Previous 10 | Next 10 |
DUBLIN , Oct. 23, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2019 and the implementation of a restructuring plan following a review of the company's operations, cost structure and growth opportunities. "As...
Alkermes (NASDAQ: ALKS ) has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center for ALKS 4230, an immuno-oncology drug candidate. More news on: Alkermes plc, Loews Corporation, Healthcare stocks news, Read more ...
–– Planned Phase 2 Multi-Site Trial to Evaluate ALKS 4230 in Combination With Pembrolizumab in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer –– DUBLIN , Oct. 21, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announce...
Alkermes (NASDAQ: ALKS ) is up 1.5% after disclosing it's gotten a tentative FDA approval for Vumerity (diroximel fumarate) for treating relapsing forms of multiple sclerosis. More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more ...
DUBLIN , Oct. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, October 23, 2019 , to discuss the company's third quarter 2019 financial results. Management will also provide an up...
DUBLIN , Oct. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research at the 32 nd Annual Psych Congress (Psych Congress), which took place Oct. 3-6, 2019 in San Diego . This research reflec...
DUBLIN , Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct. 3, 2019 at 7:45 a.m. ET ( 12:45 p.m. BST ) from New York . The audi...
DUBLIN , Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of two new independent directors, Richard Gaynor , M.D. and Frank Anders (Andy) Wilson , to the company's Board of Directors. The company also announced the retirement of F...
The following slide deck was published by Alkermes plc in conjunction with this Read more ...
Orchard Therapeutics (NASDAQ: ORTX ) initiated with Overweight rating at Barclays. More news on: Orchard Therapeutics plc, Idera Pharmaceuticals, Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...